摘要
目的探讨阿立哌唑治疗老年精神分裂症患者的疗效,安全性及其对患者生活质量的影响。方法将62例老年精神分裂症患者随机分为阿立哌唑组和利培酮组各31例,疗程8周。于治疗前和治疗后2,4,6,8周采用阳性与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评定治疗过程中出现的不良反应。治疗前及8周后用生活质量综合评定问卷(GQOLI-74)评定生活质量。结果治疗后两组PANSS评分有明显下降(P<0.01),两组间比较差异无统计学意义。阿立哌唑组不良反应明显少于利培酮组(P<0.05)。阿立哌唑组GQOLI-74总分、躯体功能、社会功能维度在治疗8周后有显著性差异(t=3.36,2.63,2.53;P<0.05或0.01<),利培酮组在治疗8周后(t=1.27,1.25,1.67;P<0.05或<0.01),阿立哌唑组评分较利培酮组升高显著(P<0.01)。结论阿立哌唑较利培酮治疗老年精神分裂症患者疗效相仿,但不良反应少,耐受性好,更能提高生活质量。
Objective To evaluate the efficacy and safety of aripiprazole in the treatment of elderly patients with schizophrenia,and its impact on quality of life of patients.Methods A total of 62 elderly patients with schizophrenia were randomly divided into aripiprazole group and the risperidone group,31 cases in each course of eight weeks.Before treatment and 2,4,6 and 8 weeks after treatment,efficacy were evaluated using the Positive and Negative Syndrome Scale（PANSS）,TESS was used to assess adverse effect in the course of treatment.Quality of life was assessed with a comprehensive assessment of the quality of life questionnaire（GQOLI-74） before treatment and after 8 weeks.Results After treatment,PANSS scores significantly decreased（P0.01）,the difference between two groups was not statistically significant（P0 05）.Adverse effect in aripiprazole group was significantly less than that in risperidone group（P0.05）.In aripiprazole group,the GQOLI-74 total score,physical function,social function dimensions after 8 weeks of treatment,were significant differences to those before treatment（t=3.36,2.63,2.53;P0.05）and those in risperidone group after 8-week treatment（t=1.27,1.25,1.67;P0.05）,there was significant difference between aripiprazole group and risperidone group（P0.01）.Conclusion Aripiprazole is similar to risperidone in efficacy in the treatment of elderly schizophrenia patients but it has less adverse reactions,well tolerated,but also improves the quality of life.
出处
《中国健康心理学杂志》
2013年第6期825-826,共2页
China Journal of Health Psychology
